Literature DB >> 3206075

Oral immunization of wildlife against rabies: concept and first field experiments.

A I Wandeler1, S Capt, A Kappeler, R Hauser.   

Abstract

The possibility of immunizing carnivores against rabies with live attenuated vaccine administered by the oral route was raised by North American scientists in the 1960s. Subsequently, several American and European teams tested different vaccine strains in the laboratory for efficacy and safety and studied vaccine stabilization, vaccine delivery systems, bait acceptance by wild animals, and bait distribution schemes. The first field trial of a cloned SAD (Street Alabama Dufferin) strain in baits designed to immunize foxes orally was conducted in an Alpine valley in Switzerland in 1978. A population containing approximately 60% immune foxes at the valley entrance stopped the spread of the disease into untreated upper parts of the valley. The strategic use of oral vaccination of foxes in additional regions of Switzerland resulted in freedom from the zoonosis in four-fifths of the country.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3206075     DOI: 10.1093/clinids/10.supplement_4.s649

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  24 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.

Authors:  Ling Zhao; Harufusa Toriumi; Hualei Wang; Yi Kuang; Xiaofeng Guo; Kinjiro Morimoto; Zhen F Fu
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Studies on the stability of a human adenovirus-rabies recombinant vaccine.

Authors:  K K Kalicharran; V S Springthorpe; S A Sattar
Journal:  Can J Vet Res       Date:  1992-01       Impact factor: 1.310

4.  EVALUATION OF ORAL RABIES VACCINATION: PROTECTION AGAINST RABIES IN WILD CAUGHT RACCOONS ( PROCYON LOTOR).

Authors:  Jesse D Blanton; Michael Niezgoda; Cathleen A Hanlon; Craig B Swope; Jason Suckow; Brandi Saidy; Kathleen Nelson; Richard B Chipman; Dennis Slate
Journal:  J Wildl Dis       Date:  2018-03-29       Impact factor: 1.535

5.  Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine.

Authors:  K M Charlton; M Artois; L Prevec; J B Campbell; G A Casey; A I Wandeler; J Armstrong
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 6.  A review of the economics of the prevention and control of rabies. Part 2: Rabies in dogs, livestock and wildlife.

Authors:  M I Meltzer; C E Rupprecht
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

7.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Rabies in a nine-year-old child: The myth of the bite.

Authors:  Olivier Despond; Marisa Tucci; Hélène Decaluwe; Marie-Claude Grégoire; Jeanne S Teitelbaum; Nathalie Turgeon
Journal:  Can J Infect Dis       Date:  2002-03

Review 9.  Current Status of Rabies and Its Eradication in Eastern and Southeastern Europe.

Authors:  Ivana Lojkić; Ivana Šimić; Tomislav Bedeković; Nina Krešić
Journal:  Pathogens       Date:  2021-06-12

10.  Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations.

Authors:  Ming Zhou; Guoqing Zhang; Guiping Ren; Clement W Gnanadurai; Zhenguang Li; Qingqing Chai; Yang Yang; Christina M Leyson; Wenxue Wu; Min Cui; Zhen F Fu
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.